Talquetamab Dose Modifications May Lower AEs While Maintaini

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Related Keywords

United States , San Francisco , California , American , Talquetamab Talvey , Helen Diller Family Comprehensive Cancer Center , American Society Of Hematology Annual Meeting , University Of California , Myeloma Program , Hematology Annual , Ajai Chari , Multiple Myeloma Program , Diller Family Comprehensive Cancer ,